ftdp-17-genetics-mapt-mutations

Overview

flowchart TD
    MAPT["MAPT"] -->|"associated with"| TAU["TAU"]
    MAPT["MAPT"] -->|"encodes"| n0N3R["0N3R"]
    MAPT["MAPT"] -->|"associated with"| NEURODEGENERATION["NEURODEGENERATION"]
    MAPT["MAPT"] -->|"associated with"| DEMENTIA["DEMENTIA"]
    MAPT["MAPT"] -->|"encodes"| MICROTUBULE_ASSOCIATED_PROTEIN["MICROTUBULE-ASSOCIATED PROTEIN TAU"]
    MAPT["MAPT"] -->|"inhibits"| Microtubule_Stability["Microtubule Stability"]
    MAPT["MAPT"] -->|"involved in"| Tau_Hyperphosphorylation["Tau Hyperphosphorylation"]
    MAPT["MAPT"] -->|"involved in"| Tau_Aggregation["Tau Aggregation"]
    MAPT["MAPT"] -->|"involved in"| Microtubule_Stabilization["Microtubule Stabilization"]
    MAPT["MAPT"] -->|"interacts with"| Microtubules["Microtubules"]
    MAPT["MAPT"] -->|"modulates"| Tau_Propagation["Tau Propagation"]
    MAPT["MAPT"] -->|"binds"| Microtubule["Microtubule"]
    MAPT["MAPT"] -->|"interacts with"| Microtubule["Microtubule"]
    MAPT["MAPT"] -->|"biomarker for"| Frontotemporal_Degeneration["Frontotemporal Degeneration"]
    style MAPT fill:#4fc3f7,stroke:#333,color:#000

Frontotemporal Dementia with Parkinsonism linked to Chromosome 17 (FTDP-17) is caused by autosomal dominant mutations in the MAPT gene (Microtubule-Associated Protein Tau). Over 50 pathogenic mutations have been identified, making FTDP-17 one of the most genetically heterogeneous neurodegenerative disorders. This page focuses on the molecular mechanisms by which these mutations cause disease.

MAPT Gene Structure and Alternative Splicing

Exon 10 Splicing Regulation

The MAPT gene contains 16 exons, with exon 10 being critically important because it encodes the second microtubule-binding repeat. Alternative splicing of exon 10 determines whether the resulting tau protein contains 3 repeats (3R) or 4 repeats (4R) of the microtubule-binding domain:

• 3R tau: Exon 10 excluded — results from inclusion of exon 10a (11 amino acids)

• 4R tau: Exon 10 included — standard protein

In the normal adult human brain, the 3R:4R ratio is approximately 1:1. This balance is essential for proper microtubule dynamics, as 4R tau binds microtubules more strongly than 3R tau.

Splicing Regulatory Elements

Exon 10 splicing is regulated by multiple elements:

• Exonic splicing enhancers (ESEs): Bound by SR proteins (serine/arginine-rich proteins)

• Exonic splicing silencers (ESSs): Bound by hnRNPs

• Intronic branch points and polypyrimidine tracts

Mutations in these regulatory regions disrupt the delicate balance of splicing, leading to altered 3R/4R ratios.

Pathogenic MAPT Mutations

Mutation Categories

FTDP-17 mutations can be divided into two major functional categories:

1. Missense Mutations (Coding Region)

Missense mutations alter the amino acid sequence of tau protein, affecting its biophysical properties:

The P301L mutation is the most studied and most common FTDP-17 mutation. It reduces microtubule binding affinity by approximately 4-fold and dramatically increases the propensity for aggregation into paired helical filaments.

2. Splicing Mutations (Intronic/Exonic)

Splicing mutations affect the alternative splicing of exon 10, leading to increased production of 4R tau isoforms:

The intron 10 mutations (+3, +12, +14, +16) are particularly important because they disrupt a stem-loop structure that normally regulates exon 10 splicing.

Molecular Mechanisms of Neurodegeneration

Loss of Microtubule Binding Function

Tau’s primary physiological function is to stabilize microtubules. Mutations that reduce microtubule binding lead to:

1. Microtubule destabilization: Reduced axonal transport efficiency

2. Neuronal transport deficits: Impaired delivery of organelles and proteins to synapses

3. Axonal degeneration: Progressive loss of axonal integrity

The P301L mutation reduces tau’s ability to promote microtubule assembly by approximately 75%, leading to significant disruption of axonal transport.

Gain of Toxic Aggregation Function

Mutations that promote aggregation lead to:

1. Hyperphosphorylation: Mutations alter the susceptibility of tau to kinase/phosphatase regulation

2. Filament formation: Pathological tau assembles into paired helical filaments (PHFs) and straight filaments

3. Neurofibrillary tangle (NFT) formation: Aggregated tau accumulates in neuronal cell bodies

Alteration of the 3R/4R Tau Ratio

Splicing mutations that increase 4R tau production lead to:

1. 4R tau predominance: 4R tau binds microtubules more strongly and aggregates more readily

2. Imbalanced proteostasis: The altered ratio disrupts normal tau turnover

3. Selective vulnerability: Certain neuronal populations are more susceptible to 4R tau toxicity

Dysregulation of Signaling Pathways

Mutant tau can dysregulate multiple signaling pathways:

• MAPK activation: Tau promotes nuclear translocation of MAPK, affecting gene expression^{1Tau promotes neurodegeneration and nuclear translocation of MAPK2004}

• ** GSK3β dysregulation**: Altered tau function affects this major tau kinase

• cAMP/PKA signaling: Altered through tau’s interaction with various effectors

Penetrance and Phenotypic Variation

Age of Onset

FTDP-17 typically presents between 40-60 years of age, though onset can vary:

• P301L: 45-55 years

• P301S: 50-60 years

• +3 intronic: 40-55 years

• V337M: 50-60 years

• R406W: 55-65 years

Phenotypic Variability

Even within families carrying the same mutation, phenotype can vary significantly. This suggests:

• Modifier genes: Other genetic variants influence phenotype

• Environmental factors: Lifestyle and environmental exposures modify expression

• Stochastic factors: Random variation in neuronal vulnerability

Animal Models of FTDP-17

Transgenic Mouse Models

Several mouse models have been developed to study FTDP-17 mechanisms:

These models demonstrate that mutant tau is sufficient to cause neurodegeneration and cognitive deficits.

Therapeutic Implications

Targeting Mutant Tau

Understanding the molecular mechanisms has informed therapeutic strategies:

1. Microtubule stabilizers: Compensate for loss of tau function

2. Aggregation inhibitors: Prevent mutant tau from forming filaments

3. ASO therapy: Reduce overall MAPT expression

4. Splicing modifiers: Restore normal 3R/4R ratio for splicing mutations

Biomarker Development

Cerebrospinal fluid biomarkers for FTDP-17 include:

• Total tau (elevated)

• Phosphorylated tau (elevated at specific sites)

• 4R tau isoforms (increased relative to 3R)^{2P301L mutation in the MAPT gene causing FTDP-17: effect on cerebrospinal fluid biomarkers2012 · J Neurol · DOI 10.1007/s00415-012-6446-1Open reference}

Cross-References

• FTDP-17 disease page

• MAPT gene

• Tau protein

• 4R-Tauopathy mechanisms

• Tau filament structures